看多
ONTX: Start of Phase 1 trials; very large gap to fill

This stock had 100M volume today-- which is unusual, therefore significant. I did some forensic analysis of their news and it appears that they had a phase 3 survival events failure which means that the meds they were testing did not increase the chances of survival among cancer patients.
Now they start over again (Phase 1) on their other cancer drugs.
I noticed that they tried to push these cancer drugs as potential COVID-19 treatments but nobody bought the news and it appears that the scientific community didn't really see any potential as a treatment.
I don't plan to take any positions in this stock but I am sure that this chart will be of interest to somebody.
Now they start over again (Phase 1) on their other cancer drugs.
I noticed that they tried to push these cancer drugs as potential COVID-19 treatments but nobody bought the news and it appears that the scientific community didn't really see any potential as a treatment.
I don't plan to take any positions in this stock but I am sure that this chart will be of interest to somebody.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。